المؤلفون: Markus Borner, Damien Dietrich, Richard Herrmann, Daniel Rauch, Marie Wernli, Jacqueline Simone Bernhard, Arnaud Roth, Piercarlo Saletti, Doris Lanz, Patrik Olivier Brauchli, Dieter Koeberle, Hanspeter Honegger, R. A. Popescu

المصدر: Annals of Oncology, Vol. 16, No 2 (2005) pp. 282-8

مصطلحات موضوعية: Adult, Male, Antimetabolites, Antineoplastic, medicine.medical_specialty, Phases of clinical research, Antimetabolites, Antineoplastic/administration & dosage/adverse effects/therapeutic use, Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives/therapeutic use, ddc:616.07, Neutropenia, Irinotecan, Deoxycytidine, Gastroenterology, Drug Administration Schedule, Capecitabine, Internal medicine, medicine, Clinical endpoint, Humans, Infusions, Intravenous, Fluorouracil/analogs & derivatives, Aged, ddc:616, XELIRI, ddc:617, Performance status, business.industry, Camptothecin/administration & dosage/adverse effects/analogs & derivatives/therapeutic use, Hematology, Middle Aged, medicine.disease, Antineoplastic Agents, Phytogenic, Confidence interval, Surgery, Treatment Outcome, Oncology, Antineoplastic Agents, Phytogenic/administration & dosage/adverse effects/therapeutic use, Colorectal Neoplasms/drug therapy/pathology, Quality of Life, Camptothecin, Female, Fluorouracil, Colorectal Neoplasms, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098f35887ea4bb064f93c952124d315d
https://doi.org/10.1093/annonc/mdi047